Guerbet

2019 annual results - Seite 2

- CT/Cath Lab⁽²⁾ sales grew 5.2% to €439.5 million at constant exchange rates thanks to double-digit sales growth of Optiray over the period (€444.6 million at current exchange rates). This strong growth, combined with the stability of Xenetix sales, illustrates Guerbet’s market penetration in this segment.

Intervention Imaging now represents just over 9% of the Group’s revenue. It posted revenue at constant exchange rates of €73.5 million, up 12.5% (€75.5 million at current exchange rates).

A financial year marked primarily by expenditures for future growth

IFRS 16 on the recognition of leases for consolidated financial statements entered into force on 1 January 2019. Guerbet decided to apply this standard on a simplified retrospective basis, which does not provide for restatement of the previous financial year. For comparison purposes, the 2019 figures are presented after application of IFRS 16 and then before application of IFRS 16 to make them comparable with the 2018 figures.

In millions of euros Consolidated financial statements (IFRS)	2018 Published	2019 Published (With IFRS 16)	2019 (Without IFRS 16)
Revenue	789.6	816.9
EBITDA (3)	110.6	111.5	101.8
% of revenue	14.0%	13.7%	12.5%
Operating income	69.9	51.7	51.6
% of revenue	8.9%	6.3%	6.3%
Net income	46.8	37.3	37.6
% of revenue	5.9%	4.6%	4.6%
Net Debt	308.7	296.5	280.5

Reported EBITDA totalled €111.5 million, including €9.7 million for the elimination of rents due to the implementation of IFRS 16.